BRIEF published on 12/29/2025 at 08:05, 14 days 4 hours ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 14 days 4 hours ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 21 days 5 hours ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 21 days 5 hours ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
PRESS RELEASE published on 12/22/2025 at 07:00, 21 days 5 hours ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 1 month 28 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 2 months 13 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 3 months 12 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 3 months 12 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 3 months 12 days ago rapport financier semestriel 2025
Published on 01/12/2026 at 12:00, 46 minutes ago NioCorp Provides Preliminary Unaudited Financial Results for the Three- and Six-Month Periods Ended December 31, 2025
Published on 01/12/2026 at 12:00, 46 minutes ago Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access
Published on 01/12/2026 at 12:00, 46 minutes ago Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment
Published on 01/12/2026 at 11:30, 1 hour 16 minutes ago FireFox Identifies Promising New Drill Targets at Mustajärvi Gold Project, Lapland, Finland
Published on 01/12/2026 at 09:01, 3 hours 45 minutes ago Apex Secures Drill Contractor and Sets Planned Mobilization for Drilling at Rift
Published on 01/12/2026 at 12:15, 31 minutes ago BIRKENSTOCK ANNOUNCES PRELIMINARY FISCAL FIRST QUARTER (ENDED DECEMBER 31, 2025) REVENUE OF €402 MILLION, GROWTH OF 17.8% IN CONSTANT CURRENCY; REPORT DATE AND CONFERENCE CALL
Published on 01/12/2026 at 12:05, 41 minutes ago LEGO® Education Announces Hands-on Computer Science & AI Learning Solution
Published on 01/12/2026 at 11:30, 1 hour 16 minutes ago Infosys and ATP Unveil 'Ally', an AI Chatbot to Elevate Fan Experience, and Announce Extension of Partnership Through 2028
Published on 01/12/2026 at 11:05, 1 hour 41 minutes ago Windrose Consulting Group Expands Greater China and APAC Expertise with Acquisition of Zenith Access Network
Published on 01/12/2026 at 10:10, 2 hours 36 minutes ago Personnel News: REPLOID Group AG expands Director-level leadership team
Published on 01/12/2026 at 09:00, 3 hours 46 minutes ago Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Published on 01/09/2026 at 18:30, 2 days 18 hours ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 19 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 19 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
